| Literature DB >> 32544083 |
Yong Wu1,2, Lingfang Xia1,2, Ping Zhao3, Yu Deng4, Qinhao Guo1,2, Jun Zhu1,2, Xiaojun Chen1,2, Xingzhu Ju1,2, Xiaohua Wu1,2.
Abstract
High-grade serous ovarian cancer (HGSOC) is a heterogeneous disease with diverse clinical outcomes, highlighting a need for prognostic biomarker identification. Here, we combined tumor microenvironment (TME) scores with HGSOC characteristics to identify immune-related prognostic genes through analysis of gene expression profiles and clinical patient data from The Cancer Genome Atlas and the International Cancer Genome Consortium public cohorts. We found that high TME scores (TMEscores) based on the fractions of immune cell types correlated with better overall survival. Furthermore, differential expression analysis revealed 329 differentially expressed genes between patients with high vs. low TMEscores. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that these genes participated mainly in immune-related functions and, among them, 48 TME-related genes predicted overall survival in HGSOC. Seven of those genes were associated with prognosis in an independent HGSOC database. Finally, the two genes with the lowest p-values in the prognostic analysis (GBP1, ETV7) were verified through in vitro experiments. These findings reveal specific TME-related genes that could serve as effective prognostic biomarkers for HGSOC.Entities:
Keywords: ICGC; TCGA; high-grade serous ovarian cancer; overall survival; tumor microenvironment score
Year: 2020 PMID: 32544083 PMCID: PMC7343445 DOI: 10.18632/aging.103199
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Association between the TMEscore and prognosis in TCGA data analyzed by the CIBERSORT algorithm. (A) Workflow of the current study. (B) Based on the median TMEscore values, patients with HGSOC were divided into the high and low TMEscore groups. (C) As shown in the Kaplan-Meier plot, the median survival time in the high TMEscore group was longer than that in the low score group (p=0.0036). (D) Distribution of TMEscores by tumor stage for HGSOC patients. The boxplot shows that there was no association between tumor stage and TMEscore.
Clinicopathological characteristics of 361 patients with HGSOC.
| Age | >=59 | 182 |
| <59 | 179 | |
| Stage | I | 1 |
| II | 20 | |
| III | 283 | |
| IV | 54 | |
| Not available | 3 | |
| OS time (months) | <12 | 65 |
| >=12 | 296 |
Figure 2DEG profiles by TMEscore in HGSOC. (A) Heatmap of the DEGs between the top half (high score) vs. bottom half (low score) of TMEscore values. A |log(fold change)|≥1 and an adjusted p-value < 0.05 were set as the cutoff criteria to screen for DEGs. (B) Volcano plot of gene expression profile data for patients with high and low TMEscores. (C–F) Functional enrichment analysis including Biological Process (BP), Cellular Components (CC), and Molecular Functions (MF) categories as well as KEGG pathways for 329 DEGs.
Figure 3Discovery of prognostic TME-related DEGs with functional annotations in TCGA. (A) Kaplan-Meier survival curves were generated for selected DEGs with prognostic significance by a log-rank test. OS=overall survival time in months. (B–E) GO term and KEGG pathway analyses with the 48 prognostic DEGs.
Figure 4Construction of the PPI network for the 48 prognostic DEGs. (A) The PPI network was constructed using the 48 prognostic DEGs with the R software package STRINGdb. (B) MCODE was used to identify the main coregulated modules. The most significant module is indicated in two closely related subgroups.
Figure 5Validation of prognostic DEGs extracted from the TCGA database in the ICGC cohort. (A–G) Kaplan-Meier survival curves were generated for seven validated DEGs in an additional cohort of 81 HGSOC patients from the ICGC. p<0.05 by a log-rank test. OS=overall survival time in days.
Figure 6(A) The protein levels of GBP1, ETV7 and CXCL13 were measured by western blotting in A2780 cells transfected with siRNAs. (B) CCK-8 assays were performed to evaluate the proliferation of GBP1-, ETV7- and CXCL13-knockdown cells. (C) The colony-forming ability of A2780 cells was assessed to determine the effects of GBP1, ETV7 or CXCL13 downregulation on cell growth. (D) The invasion potential of cells was assessed using a Transwell assay. The scale bar represents 100 μm. NC: negative control. * indicates p< 0.05.
Figure 7Levels of GBP1 and ETV7 expression correlated with overall survival in HGSOC. (A) Representative images of GBP1 expression in HGSOC tissues, visualized at 40× and 200× magnification. (B) Distribution of the immunoreactive score (IRS) in an HGSOC TMA. (C) Kaplan-Meier survival curve with log-rank analysis of overall survival showed statistical significance between the curves of patients with high GBP1 expression and those with low GBP1 expression (log-rank test, p=0.0003). (D) Univariate analysis was performed in 165 HGSOC patients. All bars correspond to 95% confidence intervals. (E) Multivariate analysis was performed in 165 HGSOC patients. All bars correspond to 95% confidence intervals. (F–G) Expression levels of ETV7 and CXCL13 were measured in HGSOC tissues compared with controls. Moreover, Kaplan-Meier method indicated the prognostic significance of ETV7 and CXCL13.
Correlation between GBP1 and clinicopathological parameters.
| Age (years) | 1.311 | 0.252 | |||
| ≤ 65 | 140 (84.8) | 78 | 62 | ||
| > 65 | 25 (15.2) | 17 | 8 | ||
| Size (cm) | 0.057 | 0.811 | |||
| ≤ 5 | 89 (53.9) | 52 | 37 | ||
| > 5 | 76 (46.1) | 43 | 33 | ||
| FIGO stage | 0.198 | 0.657 | |||
| III | 157 (95.2) | 91 | 66 | ||
| IV | 8 (4.8) | 4 | 4 | ||
| Residual tumor margins | 3.177 | 0.210 | |||
| ≤1 cm | 113 (68.5) | 59 | 54 | ||
| >1 cm | 52 (31.5) | 35 | 17 | ||
| Ascites (ml) | 0.455 | 0.500 | |||
| ≤1500 | 94 (57.0) | 52 | 42 | ||
| >1500 | 71 (43.0) | 43 | 28 | ||
| Diaphragmatic metastasis | 3.830 | 0.050 | |||
| Yes | 83 (50.3) | 54 | 29 | ||
| No | 82 (49.7) | 41 | 41 | ||
| Mesenteric metastasis | 2.991 | 0.084 | |||
| Yes | 86 (52.1) | 55 | 31 | ||
| No | 79 (47.9) | 40 | 39 | ||